Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.

CONCLUSIONS: Rapamycin treatment was well tolerated, reduced mTOR signaling and tumor growth, and resulted in significant clinical responses despite the brief treatment duration, thus supporting the potential role of mTOR inhibitors in treatment regimens for HNSCC. PMID: 30420444 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30420444?dopt=Abstract

Source: Clinical Cancer Research - November 12, 2018 Category: Cancer & Oncology Authors: Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin KB, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross LA, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS Tags: Clin Cancer Res Source Type: research